NASDAQ:VALN - Nasdaq - US92025Y1038 - ADR - Currency: USD
7.68
+0.09 (+1.23%)
The current stock price of VALN is 7.68 USD. In the past month the price increased by 33.57%. In the past year, price increased by 5.93%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.53 | 336.11B | ||
AMGN | AMGEN INC | 14.77 | 164.85B | ||
GILD | GILEAD SCIENCES INC | 15.01 | 144.54B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 120.61B | ||
REGN | REGENERON PHARMACEUTICALS | 12.71 | 60.80B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.87B | ||
ARGX | ARGENX SE - ADR | 102.95 | 36.15B | ||
ONC | BEONE MEDICINES LTD-ADR | 7.43 | 31.54B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.72B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.29B | ||
INSM | INSMED INC | N/A | 19.72B | ||
BIIB | BIOGEN INC | 8.31 | 19.27B |
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 695 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
VALNEVA SE - ADR
6 rue Alain Bombard
Saint-Herblain PAYS DE LA LOIRE FR
CEO: Thomas Lingelbach
Employees: 713
Phone: 33228073710
The current stock price of VALN is 7.68 USD. The price increased by 1.23% in the last trading session.
The exchange symbol of VALNEVA SE - ADR is VALN and it is listed on the Nasdaq exchange.
VALN stock is listed on the Nasdaq exchange.
11 analysts have analysed VALN and the average price target is 16.62 USD. This implies a price increase of 116.35% is expected in the next year compared to the current price of 7.68. Check the VALNEVA SE - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
VALNEVA SE - ADR (VALN) has a market capitalization of 653.04M USD. This makes VALN a Small Cap stock.
VALNEVA SE - ADR (VALN) currently has 713 employees.
VALNEVA SE - ADR (VALN) has a support level at 6.39. Check the full technical report for a detailed analysis of VALN support and resistance levels.
The Revenue of VALNEVA SE - ADR (VALN) is expected to grow by 6.9% in the next year. Check the estimates tab for more information on the VALN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
VALN does not pay a dividend.
VALNEVA SE - ADR (VALN) will report earnings on 2025-08-12.
VALNEVA SE - ADR (VALN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.15).
The outstanding short interest for VALNEVA SE - ADR (VALN) is 0.04% of its float. Check the ownership tab for more information on the VALN short interest.
ChartMill assigns a technical rating of 7 / 10 to VALN. When comparing the yearly performance of all stocks, VALN turns out to be only a medium performer in the overall market: it outperformed 54.96% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to VALN. Both the profitability and financial health of VALN have multiple concerns.
Over the last trailing twelve months VALN reported a non-GAAP Earnings per Share(EPS) of -1.15. The EPS decreased by -184.21% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 15.08% | ||
ROA | 7.48% | ||
ROE | 20.65% | ||
Debt/Equity | 1.06 |
ChartMill assigns a Buy % Consensus number of 84% to VALN. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -597.38% and a revenue growth 6.9% for VALN